ClinicalTrials.gg

Program

nizubaglustat

Also written as “AZ-3102”, “Nizubaglustat” and “AZ-3102 (Dose 1)”.

Its studies are mostly in Niemann-Pick Disease, Type C · Gangliosidoses, GM2 · Gaucher Disease, led by Azafaros.

Furthest: phase 3, since Jun 27, 20257 company-led studies, 6 open or runningNext primary completion: Jun 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Azafaros76 open or runningphase 3since Jun 27, 2025Feb 15, 2023Jun 30, 2027phase 2 · NCT07399704

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 15, 2023First study: phase 2 study in Gangliosidoses, GM2First studyNCT05758922 · 13 enrolled · Brazil
  2. Jun 27, 20253 phase 3 studiesNCT07082725, NCT07082543, NCT07054515
  3. Dec 17, 2025Phase 2 study in Gangliosidoses, GM2NCT07399704 · 21 enrolled · Brazil
  4. Jun 8, 2026Phase 2 study in Gaucher DiseaseNCT07715084 · 20 planned · India, Pakistan, Turkey (Türkiye)
  5. Oct 14, 2026Phase 3 study in Niemann-Pick Disease, Type CNCT07885917 · 218 planned

Ahead

  1. Jun 30, 2027Primary completion: phase 2 study in Gangliosidoses, GM2NCT07399704
  2. Jan 2028Primary completion: phase 2 study in Gaucher DiseaseNCT07715084
  3. Feb 6, 2028Primary completion: phase 3 study in Gangliosidoses, GM2NCT07082543
  4. May 14, 2028Primary completion: phase 3 study in Niemann-Pick Disease, Type CNCT07082725

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07885917Niemann-Pick Disease, Type C3Not yet recruitingApr 1, 2030218
NCT07715084Gaucher Disease · India, Pakistan, Turkey (Türkiye)2Not yet recruitingJan 202820
NCT07399704Gangliosidoses, GM2 · Brazil2Active, not recruitingJun 30, 202721
NCT07082725Niemann-Pick Disease, Type C · United States, Argentina, Australia and more3RecruitingMay 14, 202872
NCT07082543Gangliosidoses, GM2 · United States, Argentina, Australia and more3Active, not recruitingFeb 6, 202875
NCT07054515Niemann-Pick Disease, Type C · United States, Argentina, Australia and more3RecruitingMay 14, 2028147
NCT05758922Gangliosidoses, GM2 · Brazil2CompletedApr 19, 202413

How it is read

Names in the registry

  • “AZ-3102”, 5 entries
  • “Nizubaglustat”, 1 entry
  • “AZ-3102 (Dose 1)”, 1 entry
  • “AZ-3102 (Dose 2)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.